Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.01% intraday on Tuesday, driven by positive regulatory and analyst developments.

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Arrowhead's experimental drug, Plozasiran, for the treatment of severe hypertriglyceridemia. This designation accelerates the development and review process for drugs that show significant promise in addressing serious conditions. Arrowhead plans to complete Phase 3 studies by mid-2026 and submit a supplemental new drug application by the end of 2026.

Additionally, HC Wainwright & Co. maintained its "Buy" rating on the stock and raised the target price to $85 from $80, further bolstering investor confidence.